Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes.

Diwan A, Dibbs Z, Nemoto S, DeFreitas G, Carabello BA, Sivasubramanian N, Wilson EM, Spinale FG, Mann DL.

Circulation. 2004 Jan 20;109(2):262-8. Epub 2003 Dec 29.

2.

Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype.

Dibbs ZI, Diwan A, Nemoto S, DeFreitas G, Abdellatif M, Carabello BA, Spinale FG, Feuerstein G, Sivasubramanian N, Mann DL.

Circulation. 2003 Aug 26;108(8):1002-8. Epub 2003 Aug 11.

3.

Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor.

Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, Spinale FG, Mann DL.

Circulation. 2001 Aug 14;104(7):826-31.

4.

Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy.

Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, Feldman AM.

Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12746-51.

5.

Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction.

Sun M, Dawood F, Wen WH, Chen M, Dixon I, Kirshenbaum LA, Liu PP.

Circulation. 2004 Nov 16;110(20):3221-8. Epub 2004 Nov 8.

6.

MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure.

Li YY, Kadokami T, Wang P, McTiernan CF, Feldman AM.

Am J Physiol Heart Circ Physiol. 2002 Mar;282(3):H983-9.

7.

Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression.

Engel D, Peshock R, Armstong RC, Sivasubramanian N, Mann DL.

Am J Physiol Heart Circ Physiol. 2004 Sep;287(3):H1303-11.

8.

Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state.

Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, Kassiri Z, Kirshenbaum LA, Arnold M, Khokha R, Liu PP.

Circulation. 2007 Mar 20;115(11):1398-407. Epub 2007 Mar 12.

9.

Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice.

Kassiri Z, Oudit GY, Sanchez O, Dawood F, Mohammed FF, Nuttall RK, Edwards DR, Liu PP, Backx PH, Khokha R.

Circ Res. 2005 Aug 19;97(4):380-90. Epub 2005 Jul 21.

10.

TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction.

Tian H, Cimini M, Fedak PW, Altamentova S, Fazel S, Huang ML, Weisel RD, Li RK.

J Mol Cell Cardiol. 2007 Dec;43(6):733-43. Epub 2007 Sep 14.

PMID:
17945252
11.

TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling.

Bradham WS, Moe G, Wendt KA, Scott AA, Konig A, Romanova M, Naik G, Spinale FG.

Am J Physiol Heart Circ Physiol. 2002 Apr;282(4):H1288-95.

12.

Tumor necrosis factor receptor-associated factor 2 signaling provokes adverse cardiac remodeling in the adult mammalian heart.

Divakaran VG, Evans S, Topkara VK, Diwan A, Burchfield J, Gao F, Dong J, Tzeng HP, Sivasubramanian N, Barger PM, Mann DL.

Circ Heart Fail. 2013 May;6(3):535-43. doi: 10.1161/CIRCHEARTFAILURE.112.000080. Epub 2013 Mar 14.

13.
14.

Placental growth factor regulates cardiac inflammation through the tissue inhibitor of metalloproteinases-3/tumor necrosis factor-α-converting enzyme axis: crucial role for adaptive cardiac remodeling during cardiac pressure overload.

Carnevale D, Cifelli G, Mascio G, Madonna M, Sbroggiò M, Perrino C, Persico MG, Frati G, Lembo G.

Circulation. 2011 Sep 20;124(12):1337-50. doi: 10.1161/CIRCULATIONAHA.111.050500. Epub 2011 Sep 6.

15.

Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischemic remodeling.

Ramani R, Mathier M, Wang P, Gibson G, Tögel S, Dawson J, Bauer A, Alber S, Watkins SC, McTiernan CF, Feldman AM.

Am J Physiol Heart Circ Physiol. 2004 Sep;287(3):H1369-77.

16.

Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha.

Franco F, Thomas GD, Giroir B, Bryant D, Bullock MC, Chwialkowski MC, Victor RG, Peshock RM.

Circulation. 1999 Jan 26;99(3):448-54.

17.

Cell-based gene therapy modifies matrix remodeling after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-3-deficient mice.

Angoulvant D, Fazel S, Weisel RD, Lai TY, Fedak PW, Chen L, Rafati S, Seneviratne CK, Degousee N, Li RK.

J Thorac Cardiovasc Surg. 2009 Feb;137(2):471-80. doi: 10.1016/j.jtcvs.2008.08.031.

18.

Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha.

Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM.

Circ Res. 1997 Oct;81(4):627-35.

19.

Cardiac hypertrophy is enhanced in PPAR alpha-/- mice in response to chronic pressure overload.

Smeets PJ, Teunissen BE, Willemsen PH, van Nieuwenhoven FA, Brouns AE, Janssen BJ, Cleutjens JP, Staels B, van der Vusse GJ, van Bilsen M.

Cardiovasc Res. 2008 Apr 1;78(1):79-89. doi: 10.1093/cvr/cvn001. Epub 2008 Jan 10.

20.

Targeted deletion of class A macrophage scavenger receptor increases the risk of cardiac rupture after experimental myocardial infarction.

Tsujita K, Kaikita K, Hayasaki T, Honda T, Kobayashi H, Sakashita N, Suzuki H, Kodama T, Ogawa H, Takeya M.

Circulation. 2007 Apr 10;115(14):1904-11. Epub 2007 Mar 26.

Items per page

Supplemental Content

Write to the Help Desk